To learn more about CIBINQO, schedule a call with your product representative
A quick reference guide that outlines what you need to know about starting appropriate patients on CIBINQO—from the initial prescription through the first few weeks of treatment and beyond
Describes key measurements used to assess the severity of atopic dermatitis
See skin clearance and itch relief data
** This is an optional area where footnotes can live.
CIBINQO (abrocitinib) is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
CIBINQO is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.